Abstract
Metabolic Syndrome (MetS) can be defined as a cluster of cardio-metabolic dysfunctions characterized by the increase in fasting blood sugar, abdominal circumference, hypertension (HTN), triglycerides (TG) and reduction in high-density lipoprotein cholesterol (HDL) [1]. The prevalence of MetS is increasing all over the world with different regions having individual clusters of epidemic risk factors and there is evidence of a high prevalence of MS and diabetes in Asians [2,3]. Affecting approximately 25% of the world population, MetS accounts for 7% of overall mortality and 17% of deaths associated with cardiovascular disease (CVD). The literature emphasizes that individuals with MetS are two times more likely to die, regardless of the cause; three times more likely to have a heart attack and/or stroke; and five times more likely to develop type 2 diabetes (T2DM) [4,5].
Highlights
Metabolic Syndrome (MetS) can be defined as a cluster of cardio-metabolic dysfunctions characterized by the increase in fasting blood sugar, abdominal circumference, hypertension (HTN), triglycerides (TG) and reduction in high-density lipoprotein cholesterol (HDL) [1]
Affecting approximately 25% of the world population, MetS accounts for 7% of overall mortality and 17% of deaths associated with cardiovascular disease (CVD)
The patient populations that we must recognize as being at higher risk of complications from metabolic syndrome or prediabetes include those with known atherosclerosis and vascular disease, a positive family history and genetic background, and phenotypes of insulin resistance [16]
Summary
Metabolic Syndrome (MetS) can be defined as a cluster of cardio-metabolic dysfunctions characterized by the increase in fasting blood sugar, abdominal circumference, hypertension (HTN), triglycerides (TG) and reduction in high-density lipoprotein cholesterol (HDL) [1]. The prevalence of MetS is increasing all over the world with different regions having individual clusters of epidemic risk factors and there is evidence of a high prevalence of MS and diabetes in Asians [2,3]. First describing MetS in 1988, Reaven discussed several metabolic findings with this syndrome and proposed that the central characteristic is insulin resistance with an increased risk for diabetes and CVD [5,6]. Metabolic syndrome (MetS) is a cluster of metabolic factors. The aim of this study was to determine the prevalence of type 2 diabetes mellitus (T2DM) in MetS in Saudi population
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have